Lysine-Specific Demethylase 1 (LSD1/KDM1A) Contributes to Colorectal Tumorigenesis via Activation of the Wnt/β-Catenin Pathway by Down-Regulating Dickkopf-1 (DKK1)

Zebin Huang¹, Shangze Li², Wei Song¹, Xin Li², Qinshan Li¹, Zeyan Zhang², Yongqing Han¹, Xiaodong Zhang², Shiyong Miao¹, Runlei Du²*, Linfang Wang¹*

¹ National Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Tsinghua University, Beijing, China, ² Department of Cellular and Developmental Biology, College of Life Sciences, Wuhan University, Wuhan, China

Abstract

We collected paired samples of tumor and adjacent normal colorectal tissues from 22 patients with colorectal carcinoma to compare the differences in the expression of lysine specific demethylase 1 (LSD1) in these two tissues. The results showed that in 19 paired samples (86.4%), LSD1 is more highly expressed in tumor tissue than in normal tissue. To explore the role of LSD1 in colorectal tumorigenesis, we used somatic cell gene targeting to generate an LSD1 knockout (KO) HCT 116 human colorectal cancer cell line as a research model. The analysis of phenotypic changes showed that LSD1 KO colorectal cancer cells are less tumorigenic, both in vivo and in vitro. The differential expression analysis of the cells by mRNA sequencing (RNA-Seq) yielded 2,663 differentially expressed genes, and 28 of these genes had highly significant differences (Q < 0.01). We then selected the 4 colorectal cancer-related genes ADM, DKK1, HAS3 and SMURF2 for quantitative real-time PCR verification. The results showed that the differences in the expression of ADM, DKK1 and HAS3 were consistent with those measured using the RNA-Seq data. As DKK1 was the gene with the most significant differential expression, we analyzed the key proteins of the DKK1-related Wnt/β-catenin signaling pathway and found that, after knocking out LSD1, the amount of free β-catenin translocated to the nucleus was significantly reduced and that the transcription of the signaling pathway target gene c-Myc was down-regulated. Our studies show that LSD1 activates the Wnt/β-catenin signaling pathway by down-regulating the pathway antagonist DKK1, which may be one of the mechanisms leading to colorectal tumorigenesis.

Citation: Huang Z, Li S, Song W, Li X, Li Q, et al. (2013) Lysine-Specific Demethylase 1 (LSD1/KDM1A) Contributes to Colorectal Tumorigenesis via Activation of the Wnt/β-Catenin Pathway by Down-Regulating Dickkopf-1 (DKK1). PLoS ONE 8(7): e70077. doi:10.1371/journal.pone.0070077

Editor: Rajeev Samant, University of Alabama at Birmingham, United States of America

Received January 5, 2013; Accepted June 14, 2013; Published July 26, 2013

Copyright: © 2013 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by the National Basic Research Program of China (2011CB944302, 2011CB944404, http://www.nsfc.gov.cn), the State Key Laboratory Special Fund (2060204, http://www.chinalab.gov.cn), and the National Natural Science Foundation of China (81270306, 30971499, http://www.nsfc.gov.cn). The experimental study was performed in compliance with the laws of the People’s Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: runleidu@whu.edu.cn (RD); wang.linfang@imicams.ac.cn (LW)

Introduction

Colorectal cancer is one of the most prevalent types of malignant cancer worldwide. As in other cancers, the development of colorectal cancer requires the involvement of multiple genes and the gradual accumulation of mutations, which is primarily related to the instability of oncogenes, cancer suppressor genes, and growth factors [1]. A detailed understanding of the molecular mechanisms and signaling pathways may provide knowledge for the treatment and prevention of colorectal cancer.

Histone methylation is a major determinant of chromatin structure and function and has been shown to play critical roles in heterochromatin formation, X-chromosome inactivation, transcriptional regulation and DNA repair [2]. Histone methylation was considered to be a permanent epigenetic mark until the first demethylase, named lysine specific demethylase 1 (LSD1, also known as KDM1A and AOF2), was identified in 2004 [3]. Since then, histone methylation has been shown to be a dynamic process that is regulated via the addition of methyl groups by methylases and the removal of methyl groups by demethylases. As a member of the monoamine oxidase (MAO) family, LSD1 catalyzes the specific demethylation of both mono- and di-methylated lysine 4 (K4) or lysine 9 (K9) of histone H3 (H3K4me1/2 or H3K9me1/2) via a process that requires flavin adenine dinucleotide (FAD) as an essential redox cofactor [3,4]. The methylation of specific lysine residues on histones has been linked with either transcriptional activation or repression: H3K4 methylation correlates with transcriptional activation, while H3K9 methylation with repression [3]. Thus, LSD1 plays an important role in transcriptional regulation [3,6]. It can selectively initiate or repress the transcription of target genes via demethylation of H3K4 or H3K9 by interacting with a variety of molecular partners. LSD1 participates in transcriptional repression as part of various protein complexes that contain several transcriptional corepressors.
including the REST, CoREST, RCOR2, BHC30, HDAC1/2, CdBP, BRAF35, NuRD etc. [7,8,9,10], and mediates the demethylation of H3K4me1/2. In contrast, when LSD1 interacts with androgen receptor (AR) or estrogen receptor (ER), it mediates the demethylation of H3K9me1/2 to promote transcription [3,4]. In addition to histone substrates, LSD1 has also been shown to demethylate lysine residues at several non-histone substrates, such as p53 [11], Dnm1 [12], E2F1 [13], and MYPT1 [14]. Additional substrates of LSD1 remain to be discovered. The ability to regulate such a wide range of substrates has linked LSD1 to a broad spectrum of biological processes, including cell proliferation [15], chromosome segregation [16], hematopoiesis [17], spermatogenesis [18], adipogenesis [19], regulation of stem cell pluripotency [20], and embryonic development [21]. The dysregulation of LSD1 activity has an important role in human tumorigenesis [14], and studies have already been performed on chromosome segregation [16], hematopoiesis [17], spermatogenesis [18], adipogenesis [19], regulation of stem cell pluripotency [20], and embryonic development [21]. The dysregulation of LSD1 activity has an important role in human tumorigenesis [14], and studies have already been performed on chromosome segregation [16], hematopoiesis [17], spermatogenesis [18], adipogenesis [19], regulation of stem cell pluripotency [20], and embryonic development [21].

**Materials and Methods**

**Ethics Statement**

Signed informed consent was obtained from all patients for sample collection and analysis. The study was conducted in accordance with the Helsinki Declaration for human subjects and was approved by the Institutional Review Board of the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, China. All animal experiments were performed in strict accordance with the recommendations in the Regulations for the Administration of Affairs Concerning Experimental Animals as Established by the State Science and Technology Commission of the People’s Republic of China. The protocol was approved by the Committee on the Ethics of the Care and Use of Laboratory Animals of Wuhan University (Permit Number: 11100e). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

**Clinical Specimens**

Paired samples of tumor and adjacent normal colorectal tissues were obtained at the time of surgery from 22 patients with colorectal carcinoma at Cancer Hospital, CAMS, Beijing, China. Immediately after surgical resection, the specimens were snap-frozen in liquid nitrogen and stored at −80°C until use.

**Cell Lines and Culture**

DLD-1, HCT 116, HT29, RKO, SW480, CT26 and HEK 293T cells were purchased from American Type Culture Collection (ATCC). DLD-1, and CT26 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS); HCT 116 and HT29 were cultured in McCoy’s 5a medium supplemented with 10% FBS; RKO was cultured in Eagle’s Minimum Essential medium supplemented with 10% FBS; SW480 was cultured in Leibovitz’s L-15 medium supplemented with 10% FBS; HEK 293T was cultured in Dulbecco’s Modified Eagle’s medium supplemented with 10% FBS. All cell lines were cultured in a humidified atmosphere containing 5% carbon dioxide (CO₂) and 95% air at 37°C. All of the media and FBS were purchased from HyClone.

**Somatic Cell Gene Targeting**

Somatic cell gene targeting was performed as described previously [35,36]. Briefly, an 837 bp fragment from intron 6 to exon 7 of the LSD1 locus was amplified for 25 cycles from genomic DNA as the left homology arm (HA) using the following primers: P1, 5′-GGGAAUGGAGCCCTCATTGCTGAT-3′ and P2, 5′-GGAAGAATCACTTGTAAGCTGTCG-3′. Another 1041 bp fragment from exon 7 to intron 7 of the LSD1 locus was also amplified for 25 cycles from genomic DNA as the right HA using the following primers: P3, 5′-GGGTCCTAGTTGGAGGCCAGGTAAAGA-3′ and P4, 5′-GGAATAGUCTTACACCCCTGATCC-3′. Both the left and right HAs were cloned into a pAAV-LoxP-Neo knockout vector with USER enzyme (New England Biolabs). The targeting adeno-associated viruses (AAV) were packaged in 293T cells (one well of a 6-well plate at 60% confluence) by transfecting with positive clones identified by PCR and Neo-resistance. Recombinant AAV was then transduced into target cells with the Cre-recombinase to delete the drug selection marker. The correctly targeted clones were infected with adenoviruses expressing the Cre recombinase to delete the drug selection marker. The clones with successful deletion of the drug selection marker were selected by performing 30 cycles of genomic PCR, which was performed to amplify an approximately 300-bp genomic fragment in which the LoxP site was inserted (using primers P9, 5′-GGTGGCGAGCTCGAGACAGTT-3′ and P10, 5′-AAGCTTTTCAGAGTACGGT-3′). The heterozygous

**Figure 1. Expression differences of LSD1 between tumor and adjacent normal colorectal tissues.** GAPDH was used as an internal control. #1–#22, paired tissue samples 1–22.

doi:10.1371/journal.pone.0070077.g001

**LSD1 Down-Regulates DKK1 in Colorectal Cancer**

Dickkopf-1 (DKK1), a secreted protein, is known to be a regulator of the Wnt/β-catenin signaling pathway. This pathway plays an important role in development and in regulating adult stem cell systems. A variety of cellular processes are mediated by Wnt/β-catenin signaling, including proliferation, differentiation, survival, apoptosis, and cell motility [29]. Dysregulation of the pathway leads to tumorigenesis in several types of human cancers, including colorectal cancer [30,31,32,33,34]. Both LSD1 and DKK1 are associated with tumorigenesis. However, to the best of our knowledge, there is no report discusses these two proteins simultaneously. Here, we show for the first time that LSD1 contributes to colorectal tumorigenesis by down-regulating DKK1.
KO clones were infected with the same targeting viruses to target the second allele, and the neomycin resistance gene was excised as described earlier.

**Re-expression of LSD1 in KO Cell**

Full-length human LSD1 cDNA, amplified from HCT 116 cells by reverse transcription PCR (RT-PCR), was subsequently cloned into the Eukaryotic Expression Vector pcDNA3.1(+) (Invitrogen), and recombinant plasmid of pcDNA-LSD1 was constructed. Subsequently, the pcDNA-LSD1 plasmid was transfected into LSD1 KO HCT 116 cells, and selected with G418. The re-expression of LSD1 in LSD1 KO HCT 116 cell was determined by Western blot analysis.

**Western Blot Analysis**

Total protein extracts from cells and the tumor and corresponding adjacent normal colorectal tissues were prepared in lysis buffer (Promega) containing the complete cocktail of protease inhibitors (Roche). Nuclear and cytoplasmic proteins were separated using the NE-PER nuclear and cytoplasmic extraction kit (Pierce) following the manufacturer’s instructions. The protein concentrations were determined with the BCA protein assay.

Figure 2. Generation of the LSD1 KO colorectal cancer cell line. (A) Selection of colorectal cancer cell lines. (B) Diagram of the targeting strategy. The endogenous LSD1 locus is shown, along with the AAV targeting vector and the targeted allele before and after Cre-mediated recombination. PCR primers P1–P10 were described in Materials and Methods. Three STOP codons TGA were added at the end of the left HA to ensure premature termination of the transcript. L-ITR and R-ITR, left and right inverted terminal repeats, respectively; HA, homology arm; TK, TK promoter; Neo, neomycin resistance gene; polyA, polyadenylation signal. (C) Identification of LSD1 null cell lines by genomic PCR. PCR detected the WT and targeted alleles from the indicated cells using genomic DNA as template. Two independent clones for the KO are shown. The lower row with the band designated "WT" indicates that the lower band was amplified from wild-type allele. The upper row with the band designated "KO" shows that the upper band was amplified from the allele with part of exon 7 of the LSD1 knocked out and LoxP inserted. (D) Confirmation of LSD1 null cell lines by Western blot analysis. β-actin was used as an internal control.

doi:10.1371/journal.pone.0070077.g002
Figure 3. LSD1 KO colorectal cancer cells are less tumorigenic both in vivo and in vitro. (A) Proliferation assays. Approximately 1,000 cells per well of the indicated cell lines were seeded in 96-well plates. The proliferation of each clone was measured daily for 6 consecutive days by the CCK-8 method (measuring the absorbance at 450 nm) and plotted. (B) Plate colony formation. Approximately 200 cells per well of the indicated cell line were seeded in 6-well plates. Colonies were counted and their size was measured at 21 days. (C) Soft agar colony formation. Approximately 1,000 cells per well of the indicated cell line were seeded in soft agar. Colonies were counted at 21 days.
lines were seeded in 6-well plates. After 10 days in culture, the cells were stained with crystal violet, the colonies were counted and the number of colonies was plotted for each of the clones. The experiments were performed in triplicate; representative wells are shown. (C) Soft agar colony formation. Approximately 1.0×10⁶ cells per well of the indicated cell lines were suspended in soft agar medium in 6-well plates. After 10 days in culture, the colonies were then counted, and the number of colonies was plotted for each of the clones. The experiments were performed in triplicate; representative wells are shown. (D) Xenograft experiments. LSD1 KO colorectal cancer cells are less tumorigenic in vivo. Athymic nude mice were injected subcutaneously with cells from the indicated clones. Tumor sizes were measured every 3 days for approximately 3 weeks and plotted. The mice were then sacrificed, and the tumors were harvested and weighed. Each mouse grew two tumors. #1−#6, mouse 1−6 in each group. doi:10.1371/journal.pone.0070077.g003

RNA Sequencing (RNA-Seq)

Cell samples were used for single-end mRNA sequencing performed by EMITD Technology Development Co. Ltd. using a HiSeq2000 instrument (illumina). To compare mRNA expression data before and after LSD1 KO, read counts for each identified mRNA were normalized to the total number of reads in each given sample. Differential expression was evaluated using the fragments per kilobase of transcript per million fragments mapped (FPKM) method. The fold change of mRNA reads was calculated as the ratio of the KO group to the wild-type (WT) group, and Q values <0.01 were considered to indicate highly significant differences.

Quantitative Real-time PCR (qPCR)

Total cellular RNA was extracted using TRIZOL reagent (Invitrogen). Reverse transcription was performed using the ReverTra Ace -x- kit (TOYOBO). qPCR was carried out in triplicate using the Power SYBR Green Master Mix (Applied Biosystems) with a StepOnePlus (Applied Biosystems) sequence detection system. The cycling conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. Amplification of β-actin was performed in parallel for each sample and used as an internal control. The following primer pairs were used:

| Primer 1          | Primer 2          |
|------------------|------------------|
| HAS3: forward    | reverse           |
| DKK1: forward    | reverse           |
| SMURF2: forward  | reverse           |
| DKK1: forward    | reverse           |

Enzyme-linked Immunosorbent Assay (ELISA)

DKK1 levels in supernatants from cultured cells were measured using a commercial DKK1 ELISA Kit (Jiany). Prior to the assay, approximately 1.0×10⁶ cells per well were seeded in 6-well plates, and the culture media were harvested after 48 hours of culture. The ELISA was performed following the manufacturer’s instructions. Data were expressed as concentration in ng/mL produced by 1.0×10⁶ cells in 48 hours. Each assay was performed in triplicate and repeated three times.

Statistical Analysis

All experiments were independently performed at least three times in triplicate. Statistical analysis was performed using GraphPad Prism 5 software. P values were calculated using Student’s t-test. P values <0.05 were considered significant, while P values <0.01 were considered highly significant. The data are presented as the mean ± SD.
Results

LSD1 is Highly Expressed in Tumor Colorectal Tissues in Comparison to Adjacent Normal Colorectal Tissues

We collected paired samples of tumor and adjacent normal colorectal tissues from 22 patients with colorectal carcinoma to compare the differences in the expression of LSD1 in the two tissues. The result showed that in 19 pairs (86.4%) of samples, LSD1 was highly expressed in tumor tissues compared to adjacent normal tissues (Figure 1). This result suggested that LSD1 might function in colorectal tumorigenesis.

Generation of LSD1 KO HCT 116 Human Colorectal Cancer Cell Line as a Research Model for Colorectal Cancer

To explore the role of LSD1 in colorectal tumorigenesis, we used somatic cell gene targeting to generate a LSD1 KO colorectal cancer cell line as a colorectal cancer research model. We first analyzed LSD1 expression in various colorectal cell lines, including DLD-1, HCT 116, HT29, RKO, SW480 and CT26, to find one in which LSD1 was highly expressed and suited for use as the model. The result showed that all of the cell lines highly expressed LSD1 (Figure 2A). Because HCT 116 had been widely used for successful gene targeting by homologous recombination [35,37], we chose HCT 116 to generate the LSD1 KO research model. The targeting strategy is outlined in the schematic diagram in Figure 2B. Recombinant adeno-associated virus (rAAV) vectors provide an efficient means of permanently inactivating genes in human cancer cells [38,39]. In this work, we generated targeting vectors with a neomycin resistance gene so that infected cells would express the drug resistance gene only when homologous recombination occurs. Targeting was directed to exon 7 of the LSD1 gene (Figure 2B). Targeting was performed in a colon cancer cell line, HCT 116, and was initially evaluated via PCR of genomic DNA. Following disruption of the first allele, Cre recombinase was used to remove the drug-resistance cassette integrated at the targeted locus, permitting another round of targeting to disrupt the second allele. This process of targeting by rAAV infection followed by Cre recombinase-mediated excision was performed twice in sequence to disrupt both alleles of LSD1. PCR of genomic DNA from each clone was performed to verify the nature of the targeting events (Figure 2C). Finally, Western blot analysis was used to confirm the absence of protein expression (Figure 2D). Both PCR and Western blot analysis confirmed the heterozygous (LSD1+/-) and homozygous (LSD1-/-) gene disruption, and we obtained two independent LSD1 KO heterozygous and homozygous clones for these studies.

LSD1 KO Colorectal Cancer Cells Grew Slower than WT Cells

CCK-8 allows sensitive colorimetric assays for the determination of the number of viable cells in cell proliferation assays. WST-8, used in CCK-8, is reduced by dehydrogenase in the cells to give an orange colored product (formazan), which is soluble in the culture medium. The amount of the formazan dye generated by dehydrogenase in cells is directly proportional to the number of living cells. To test whether LSD1 KO affected proliferation, growth was measured by CCK-8, and the cell growth curve was plotted. The result showed that the homozygous KO cells grew more slowly than WT.
Figure 5. Global histone methylation and gene expression in WT and KO cell lines. (A) Western blot analysis of the global methylation levels of H3K4me1/2 and H3K9me1/2 of the cells before and after knocking out LSD1. H3 was used as an internal control. (B) Gene expression in WT and KO cell lines by RNA-Seq analysis. (C) RNA-Seq differential gene expression analysis of the cells before and after knocking out LSD1. Q values < 0.01. (D) qPCR verification of gene expression in WT and KO cell lines. Validation of the RNA-Seq data using the qPCR assay to establish expression ratios between the LSD1 KO and WT cell lines. The total RNA used for the qPCR assay was obtained one set of the three replicate experiments, and the qPCR data shown represent the average of three independent reactions.

doi:10.1371/journal.pone.0070077.g005
much more slowly than WT cells and that the growth rate of the heterozygous KO cells was between those of the two cell lines mentioned above (Figure 3A).

In vitro, LSD1 KO Colorectal Cancer Cells Exhibited Reduced Colony-forming Abilities

To test whether LSD1 KO affected tumorigenicity-correlated responses in vitro, we performed plate colony formation and soft agar colony formation assays. Compared with the WT cells, the homozygous KO cells exhibited a highly significant (P < 0.01) reduced colony-forming ability in the plate colony formation assay and the soft agar formation assay. Notably, the colony-forming ability of the heterozygous KO cells was between those of the two cell lines mentioned above (Figure 3B and C).

LSD1 KO Colorectal Cancer Cells were Less Tumorigenic in vivo

Tumorigenicity of the KO cells was also tested in an in vivo model. For these studies, LSD1 KO homozygous clones or WT HCT 116 cells were injected subcutaneously into nude mice. Beginning 7 days later, tumor sizes were assessed every 3 days by caliper measurements. The homozygous KO cells produced tumors that grew more slowly than those produced by the WT cells (P < 0.01). After 22 days of growth, the average tumor volume of the homozygous KO cells was approximately 5-fold smaller than those produced by the WT cells (P < 0.01) (Figure 3D).

Re-expression of LSD1 in the KO Cell Restored the Phenotype

To verify that the observed phenotype was due to disruption of the LSD1 gene and not simply due to some other mutation in the cell line, we re-expressed LSD1 in the KO cell and then repeated the cell proliferation assays and colony formation assays. Notably, the re-expression of LSD1 was sufficient to restore the phenotype (Figure 4A, B and C).

LSD1 KO did not Increase Global Histone Methylation

LSD1 is highly expressed in tumor colorectal tissues compared to adjacent normal colorectal tissues, and LSD1 KO colorectal cancer cells are less tumorigenic both in vivo and in vitro, which

| Table 1. RNA-Seq differential gene expression analysis of the cells before and after knocking out LSD1. Q values <0.01. |
|-----------------|------------------|----------------|----------------|
| Chromosome       | Gene Name        | Accession Num  | GI RPKM LSD1+/+ | RPKM LSD1−/− | RPKM Ratio |
|------------------|------------------|----------------|----------------|-------------|-----------|
| Down-regulated genes | chr2:36134782-36425014 | RRM9           | NM_001082578   | 133925802   | 22.3567   | 0         | 19.15     |
| chr1:85368607-85376182 | CREBZF          | NR_028026      | 253735743      | 17.6371     | 0.920806  | 19.15     |
| chr1:111393512-111693564 | PHLD82         | NM_001134438   | 197313729      | 25.4097     | 2.82168   | 9.01      |
| chr4:5424736-5426185 | FIP1L1          | NM_039917      | 201023333      | 46.0611     | 5.4131    | 8.51      |
| chr1:18406227-184077936 | CLCN2           | NM_004366      | 283806614      | 18.5061     | 2.21267   | 8.36      |
| chr1:76000258-76105687 | TNRC6C          | NM_001124640   | 217416331      | 17.9741     | 3.53404   | 5.09      |
| chr1:11405691-114790261 | ZBTB20          | NM_001164343   | 257900534      | 60.0398     | 13.33     | 4.50      |
| chr16:69140054-69151595 | HAS3            | NM_005329      | 20302152       | 282.114     | 82.9034   | 3.40      |
| chr11:10326517-10328943 | ADM             | NM_001124      | 4501944        | 358.132     | 113.56    | 3.15      |

| Up-regulated genes | chr7:129470574-129592817 | UBE2H          | NM_003344      | 321267497   | 48.7407   | 185.244   | 0.26      |
| chr1:62519672-62658471 | SMURF2          | NM_002739      | 56550041       | 77.4254     | 297.909   | 0.26      |
| chr1:3728373-3751548 | TIP3            | NM_014428      | 10092690       | 52.9945     | 208.328   | 0.25      |
| chr1:62223242-62340653 | SNORA76         | NR_0028995     | 91754179       | 251.869     | 1076.79   | 0.23      |
| chr1:54074000-54077417 | DKK1            | NM_0012245     | 61676924       | 382.42      | 1673.1    | 0.23      |
| chr6:2833078-2842264 | SERPINB1        | NM_003666      | 20149554       | 87.1642     | 407.857   | 0.21      |
| chr10:2106901-21165631 | NEBL            | NM_006393      | 197313771      | 5.62632     | 26.5163   | 0.21      |
| chr1:10586401-10657822 | GOLSNY          | NM_001099750   | 153090196      | 16.7722     | 89.617    | 0.19      |
| chr1:19:1782073-1812270 | ATP8B3         | NM_138813      | 55743078       | 3.96713     | 21.6199   | 0.18      |
| chr1:17250212-172580973 | C1orf9         | NM_014283      | 170784827      | 5.49381     | 30.9739   | 0.18      |
| chr1:14990641-150038792 | SYNOPO         | NM_007286      | 261278294      | 9.80218     | 70.6967   | 0.14      |
| chr2:17566401-175870170 | CHN1           | NM_001822      | 331028574      | 4.47354     | 32.9858   | 0.14      |
| chr6:6863462-6161240 | KCNA2           | NM_172130      | 315434243      | 7.08796     | 63.0558   | 0.11      |
| chr1:155108287-15511334 | RAG1AP1        | NM_018845      | 170932468      | 9.50477     | 95.1037   | 0.10      |
| chr2:20591297-5976791 | MCM8            | NM_182802      | 33469923       | 2.76332     | 32.6384   | 0.08      |
| chr2:23286596-23315441 | ENTPD4         | NM_004901      | 347543761      | 2.02587     | 29.3349   | 0.07      |
| chr2:3733156-37384319 | EIF2AK2        | NM_001135651   | 351542234      | 2.91037     | 46.3784   | 0.06      |
| chr2:20543436-26968256 | TOX2            | NM_028833      | 149408142      | 5.61672     | 99.022    | 0.06      |
| chr9:13961455-139626236 | SNHG7          | NR_024543      | 215422348      | 0           | 29.3914   | 0.00      |

doi:10.1371/journal.pone.0070077.t001
suggested that LSD1 functions in colorectal tumorigenesis. To explore the molecular basis of LSD1 and tumorigenesis, a series of experiments was performed in this laboratory. LSD1 is a demethylase, and it catalyzes the specific demethylation of H3K4me1/2 or H3K9me1/2. Here, we used Western blotting to detect changes in the global methylation levels of H3K4me1/2 and H3K9me1/2 in the cells before and after knocking out LSD1. The results showed that these global methylation levels did not change significantly (Figure 5A).

**Transcriptional Effects of LSD1 KO**

RNA-Seq was performed to analyze the differential expression of the cells before and after knocking out LSD1. Here, we found 2,663 differentially expressed genes; 102 of these genes were only expressed in the homozygous KO cells, whereas 77 were only expressed in WT cells (Figure 5B and Table S1). Statistical analysis allows us to screen out 28 genes that exhibited highly significant differences (Q < 0.01). Of these 28 genes, 9 were down-regulated after knocking out LSD1, and the remaining 19 were up-regulated (Table 1 and Figure 5C).

**Validation of mRNA Sequencing Data of 4 Colorectal Cancer-related Genes**

We selected 4 colorectal cancer-related genes, ADM, DKK1, HAS3 and SMURF2, from the 28 genes mentioned above for further confirmation using qPCR. The total RNA used for the qPCR experiments was obtained one set of the three replicate experiments, and the qPCR data shown represent the average of three independent reactions. The result showed that the differences in expression of ADM, DKK1 and HAS3 were consistent with those measured using the RNA-Seq data: ADM and HAS3 were down-regulated, whereas DKK1 was up-regulated after knocking out LSD1. However, SMURF2 expression was not significantly different before and after knocking out LSD1, as shown by qPCR (Figure 5D).

**LSD1 Activated the Wnt/β-catenin Signaling Pathway by Down-regulating the Pathway Antagonist DKK1**

Because DKK1 had the most significant differential expression before and after LSD1 KO in HCT 116 cells by both RNA-Seq and qPCR analyses (Table 1, Figure 5C and D), we chose it for further study. After knocking out LSD1, both Western blot analysis of cellular extracts (Figure 6A) and ELISA analysis of secretion in culture media (Figure 6B) showed DKK1 increased. And we found that β-catenin, the key protein of the DKK1-related Wnt/β-catenin signaling pathway, decreased, while phosphorylated-β-catenin (p-β-catenin) increased significantly (Figure 6A). Additionally, the amount of free β-catenin translocated to the nucleus was decreased (Figure 6C), and the transcription of the signaling pathway target gene, c-Myc, was down-regulated (Figure 6A). The increase of β-catenin in the nucleus is indicative of the activation of the Wnt/β-catenin signaling pathway; thus, the results indicated that in WT HCT 116 cells, LSD1 activated the Wnt/β-catenin pathway by down-regulating the DKK1 antagonist.
Wnt/β-catenin signaling pathway by down-regulating the pathway antagonist, DKK1.

Discussion

In the detection of clinical samples by Western blot analysis, we found that LSD1 was highly expressed in tumor colorectal tissues in comparison to adjacent normal colorectal tissues (Figure 1), which suggested that LSD1 might function in colorectal tumorigenesis. To explore the role of LSD1 in colorectal tumorigenesis, we used somatic cell gene targeting to generate an LSD1 KO HCT 116 human colorectal cancer cell line as a research model for colorectal cancer (Figure 2). Gene targeting is one of the advanced research techniques used to explore gene function and the regulatory role of the signaling pathway. Compared with animal gene KO, somatic cell gene KO is much easier, less costly and more rapid. In addition, this technique overcomes the shortcomings of animal embryonic lethality. In contrast to the RNAi knockdown technique, somatic cell gene KO can completely delete the target gene. When compared to over-expression technique, somatic cell gene KO can avoid the influence of unstable artificial factors from over-expression, which makes the results more credible.

In this study, compared to WT colorectal cancer cells, LSD1 KO cells were less tumorigenic both in vivo and in vitro (Figure 3), which indicates that LSD1 plays a critical role in colorectal tumorigenesis. This finding was similar to that of Jin et al. [40]. Additionally, we found that the relationship between WT and LSD1 KO colorectal cancer cell lines was in good agreement with the relationship between tumor and adjacent normal colorectal tissues, which indicates that the LSD1 KO cell line is a good model for colorectal cancer research.

LSD1 is a demethylase, and it catalyzes the specific demethylation of H3K4me1/2 or H3K9me1/2; thus, before our experiments, it was reasonable to speculate that, after knocking out LSD1, the global methylation levels of H3K4me1/2 or H3K9me1/2 would increase. Surprisingly, in the experiment, these global methylation levels did not change significantly (Figure 5A). The result suggested that some unknown mechanism may compensate for the absent demethylase catalytic activity of LSD1. The result is similar to that of Wang et al., who performed in embryonic stem cells [12].

To explore the molecular basis of LSD1 and tumorigenesis, we analyzed the differential expression of the cells before and after knocking out LSD1 by RNA-Seq and found 2,663 differentially expressed genes (Figure 5B). Gene expression data are described in detail in Table S1. Statistical analysis allowed us to screen out 23 genes that exhibited highly significant differences (Q < 0.01). Of these, 9 were down-regulated after knocking out LSD1, and the remaining 19 were up-regulated (Table 1 and Figure 5C). Interestingly, among these genes, 4 genes, including ADM [41], DKK1 [42], HAS3 [43] and SMURF2 [44], have been reported to be involved in colorectal tumorigenesis. Thus, we tried to find clues from these four for exploring the role of LSD1 in colorectal tumorigenesis. We took them for further confirmation by qPCR analysis and the results of this analysis showed that the differences in the expression of ADM, DKK1 and HAS3 were consistent with those measured using the RNA-Seq data (Table 1, Figure 5C and

Figure 7. A diagram of the Wnt/β-catenin signaling pathway. We propose that LSD1 down-regulates the Wnt/β-catenin signaling pathway antagonist, DKK1, and that this down-regulation causes free β-catenin to avoid degradation and accumulate in the cytoplasm. The free β-catenin then translocated to the nucleus, activates the transcription of the signaling pathway target gene c-Myc, and finally leads to the aberrant proliferation of cells and tumorigenesis.

doi:10.1371/journal.pone.0070077.g007
D). Because DKK1 was the gene with the most significant differential expression before and after knocking out LSD1 in HCT 116 cells, as shown by both RNA-Seq and qPCR analyses, and because it is an antagonist of the Wnt/β-catenin signaling pathway which plays an important role in development and tumorigenesis [30,31,45], we chose it for further research. Although the rest of the 2,663 differential expression genes were not analyzed further in this work, these genes do provide important reference values and clues for researchers in exploring the biological function of LSD1 and the role of LSD1 in colorectal tumorigenesis. The differential expression phenomenon observed in this work was similar to that observed by Huang et al. in their drug research. They reported that the inhibition of LSD1 in human colon carcinoma cells by biguanide and bisguanidine polyamine analogues resulted in a re-expression of aberrantly silenced genes, including SFRP1, SFRP4, SFRP5, and GATA5 [28].

The Wnt/β-catenin pathway in mammalian cells is activated when the Wnt ligand, a secreted factor, binds to cell-surface receptors of the Frizzled family and the LRPs 5/6 co-receptor. In turn, this binding leads to the inhibition of a complex comprising APC, Axin, and GSK-3β. This complex normally plays a role in the phosphorylation and degradation of β-catenin by the ubiquitin/proteosome pathway [46]. When this complex is inhibited, β-catenin accumulates and translocates to the nucleus [46], where β-catenin binds to TCF/LEF factors and up-regulates the transcription of many cancer-related genes, including c-Myc [47,48]. Constitutively active Wnt signaling is causally involved in the genesis of various cancers, including colorectal cancer [30,31]. DKK1, a Wnt antagonist, blocks the Wnt/β-catenin pathway through competitive binding to the Wnt co-receptor LRP 5/6 and the transmembrane protein Kremen1/2 [49,50]. DKK1 mediates tumor suppression in some cancer cells by blocking the Wnt/β-catenin pathway. Expression of DKK1 in these cells is associated with increased phosphorylation and degradation of β-catenin and down-regulation of c-Myc etc. oncogenes, so inhibiting cell growth [51,52,53]. In colorectal cancer, decreased DKK1 expression is observed [54,55]. DKK1 has strong antiproliferative effects in colorectal cancer cell lines [54,56] and dramatically reduces tumor burden in mouse xenografts [54]. Qi et al. reported that overexpression of DKK1 decreased the expression and intracellular distribution of β-catenin as well as the expression of c-Myc. Their study confirmed that DKK1 has inhibitory effects on colon cancer progression [42]. Overall, DKK1 is thought to act as a tumor suppressor gene. Inactivation or down-regulation of DKK1 can lead to various cancers, including colorectal cancer [54,57,58].

In our studies, we detected the key protein of the Wnt/β-catenin signaling pathway. The results showed that, after knocking out LSD1, secreted DKK1 increased, β-catenin decreased, p-β-catenin increased, and c-Myc decreased (Figure 6A and B), which suggested the decline of Wnt/β-catenin signaling pathway activation. The translocation of β-catenin to the nucleus is indicative of the activation of the Wnt/β-catenin signaling pathway. Thus, we further analyzed the protein levels of β-catenin in the cytoplasm and nucleus. We found that β-catenin was reduced in the cytoplasm and significantly reduced in the nucleus (Figure 6C). Because β-catenin was significantly reduced in the nucleus, it should also be significantly reduced in the cytoplasm. However, the experimental results showed that this protein was reduced in the cytoplasm but not as obviously as in the nucleus. We speculated that the free β-catenin in the cytoplasm is, in fact, significantly reduced but that the non-free β-catenin, which binds with E-cadherin on the inner side of the cell membrane in the cytoplasm, was also extracted due to the β-catenin/E-cadherin complexes were destroyed in the lysate during the protein extraction process. However, there was much more bound β-catenin than free β-catenin; therefore, the reduction was not as obvious as in the nucleus. Nevertheless, the experimental results still indicated that the amount of β-catenin translocated to the nucleus was significantly reduced and the obvious decline of Wnt/β-catenin signaling pathway activation.

DKK1 plays a key role here to link LSD1 to Wnt/β-catenin pathway and then to colorectal tumorigenesis. As LSD1 is a demethylase, which represses the transcription of target genes via demethylation of H3K4 by interacting with a variety of molecular partners [7,8], and LSD1 may also repress the transcription of target genes via DNA CpG dimucleotide methylation by demethylating and stabilizing Dnmt1 [12,40], we speculate that above might be two possible mechanisms of down-regulation of DKK1 by LSD1. As to the latter mechanism which involves Dnmt1, Wang et al. reported that LSD1 demethylated and stabilized Dnmt1 in embryonic stem cells [12], while Jin et al. reported that LSD1 could not perform the similar function in HCT 116 [40]. So we suggest that the former mechanism which involves H3K4 might be more possible; nevertheless, the exact mechanism needs further study.

In conclusion, based on the existing reports and our studies, it is reasonable to speculate that LSD1 contributes to colorectal tumorigenesis via activation of the Wnt/β-catenin signaling pathway by down-regulating the pathway antagonist DKK1. Specifically, LSD1 down-regulates DKK1, which allows free β-catenin to avoid phosphorylation and degradation. As a result, free β-catenin then accumulates and translocates to the nucleus, where it up-regulates the transcription of downstream target genes, including the oncogene c-Myc; the overexpression of c-Myc then causes the cells to transition to a malignant phenotype. To illustrate this mechanism, we have included a simple diagram (Figure 7). To the best of our knowledge, this is the first report that links LSD1 and DKK1 and elucidates the impact of LSD1 on the Wnt/β-catenin signaling pathway activation and the pathway target genes to reveal the role of LSD1 in colorectal tumorigenesis.

**Supporting Information**

**Table S1 RNA-Seq differential gene expression analysis of the cells before and after knocking out LSD1.**

**(XLS)**

**Acknowledgments**

We are grateful to the Core Instrument Facility of Institute of Basic Medical Sciences for instrumental assistance.

**Author Contributions**

Conceived and designed the experiments: ZH XZ SM RD LW. Performed the experiments: ZH SL WS XL QL ZZ YH. Analyzed the data: ZH XZ. Contributed reagents/materials/analysis tools: ZH SL WS XL QL ZZ YH. Performed the experiments: ZH SL WS XL QL ZZ YH. Wrote the paper: ZH.

**References**

1. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449–2460.

2. Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15: 2343–2360.
31. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 124: 783–802.
30. Ilyas M (2005) Wnt signalling and the mechanistic basis of tumour development. Nat Rev Cancer 5: 885–902.
29. Willert K, Jones KA (2006) Wnt signaling: is the party in the nucleus? Genes Dev 20: 2107–2130.
28. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, et al. (2007) Histone demethylase 1A (KDM1A) is required for maintenance of global DNA methylation. Nat Genet 39: 125–129.
27. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, et al. (2009) Lysine-specific demethylase 1 (LSD1) regulates the embryonic transcriptome and CoREST stability. Nat Genet 41: 125–129.
26. Kontaki H, Talanian I (2010) Lysine methyltransferase SET1A induces cell cycle arrest in colorectal cancer cells. Mol Cancer 9: 159–160.
25. Lv T, Yuan D, Miao X, Lv Y, Zhan P, et al. (2012) Over-expression of LSD1 Down-Regulates DKK1 in Colorectal Cancer.
24. Schenk T, Chen WC, Gollner S, Howell L, Jin L, et al. (2012) Inhibition of the TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and cancer. Cancer Res 72: 1280–1285.
23. Wu CY, Hsieh CY, Huang KE, Chang C, Kang HY (2012) Cryptotanshinone inhibits epigenetic inactivation of DICKKOPF family genes in human gastrointestinal carcinomas. Mol Cancer 11: 1098–1103.
22. Lim S, Janzer A, Becker A, Zimmer A, Schule R, et al. (2010) Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma tumors. PLoS ONE 5: e11722.
21. Zhao X, Guo C, Chen Y, Liu Y, Yu H, et al. (2009) Lrken and Cdkn1a are down-regulated in human hepatocellular carcinomas. Hepatology 50: 793–803.
20. Zhou H, Li W, Zhu S, Joo JY, Do JT, et al. (2010) Conversion of mouse epiblast to epidermis by reprogramming somatic cells to pluripotency. Stem Cells 29: 79–81.
19. Chosed R, Dent SY (2007) A two-way street: LSD1 regulates chromatin boundary formation in S. pombe and Drosophila. Mol Cell 26: 160–162.
18. Shi YJ, Matson C, Fan L, Iwas B, Taha T, et al. (2005) Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 19: 857–864.
17. Lv MG, Wynder C, Cooch N, Shiekhattar R (2006) An essential role for CoREST in nucleosomal histone 3 lyse 4 demethylation. Nature 437: 432–435.
16. Lv S, Bu W, Jiao H, Liu B, Zhu L, et al. (2010) LSD1 is required for chromosome segregation during mitosis. Eur J Cell Biol 89: 557–563.
15. Scoumanne A, Chen X (2007) The lysine-specific demethylase 1 is required for mouse spermatogenesis. Biol Reprod 77: 754–764.
14. Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, et al. (2011) Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res 71: 653–660.
13. Scoumanne A, Chen X, Que C, Chen Y (2007) The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem 282: 15471–15475.
12. Lv S, Bu W, Jiao H, Liu B, Zhu L, et al. (2010) LSD1 is required for chromosome segregation during mitosis. Eur J Cell Biol 89: 557–563.
11. Li Y, Deng C, Hu X, Patel B, Fu X, et al. (2012) Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukaemia. Oncogene 31: 5007–5018.
10. Godmann M, Auger V, Ferravollis-Aguirre V, Di Sasuro A, Sette C, et al. (2007) Dynamic regulation of histone H3 methylatation by LSD1 in 4 mammalian spermatogenesis. Biol Reprod 77: 734–746.
9. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, et al. (2009) LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138: 660–672.
8. Lee MG, Wynder C, Cooch N, Shiekhattar R (2005) An essential role for histone demethylase LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation biomarker predicting aggressive biology. Carcinogenesis 31: 512–520.
7. Zhou XL, Qin XR, Zhang XD, Ye LH (2010) Downregulation of Dickkopf-1 is a hallmark feature of colorectal cancer. Mol Cancer 9: 29676–29680.
6. Chosed R, Dent SY (2007) A two-way street: LSD1 regulates chromatin boundary formation in S. pombe and Drosophila. Mol Cell 26: 160–162.
5. Martin C, Zhang Y (2005) The diverse functions of histone lysine methylations. Nat Rev Mol Cell Biol 6: 838–849.
4. Metzger E, Wissmann M, Yu N, Muller JK, Schneider R, et al. (2005) LSD1 demethylates histone H3 lysine 9 marks to promote androgen-receptor-dependent transcription. Nature 437: 432–435.
3. Shi Y, Lan F, Matson C, Mulligan P, Weshetine JR, et al. (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941–953.
2. Metzger E, Wissmann M, Yu N, Muller JK, Schneider R, et al. (2005) LSD1 demethylates histone H3 lysine 9 marks to promote androgen-receptor-dependent transcription. Nature 437: 432–435.
1. PLOS ONE | www.plosone.org 12 July 2013 | Volume 8 | Issue 7 | e70077

LSD1 Down-Regulates DKK1 in Colorectal Cancer